Participated · Series A · Jun 2024

3DC develops and manufactures Graphene MesoSponge® (GMS), a three-dimensional graphene material with porosity, conductivity, flexibility, and corrosion resistance intended to address trade-offs in battery performance. The company was founded in February 2022 and is headquartered at Tohoku University in Sendai, with a Kawasaki office and a pilot factory in Toki, Gifu where construction of the world’s first GMS mass-production facility has begun. Following a Series A 1st-close in August 2025 and ongoing validation work, 3DC is supplying functional conductive additive GMS to numerous domestic and international battery makers for evaluation. 3DC plans to use recent and prior funding to expand its pilot factory into a mass-production plant, establish ton-scale production processes, strengthen global supply for customer evaluations and commercialization, and expand R&D talent and overseas partnerships. The company positions partnerships with established industry players and strategic investors as key to accelerating production, supply-chain stabilization, and market adoption of GMS.

Participated · Series C · Nov 2023

RUTILEA builds zero-code AI products to automate business processes and make high-precision AI immediately usable. Since founding in 2018, the company has focused on solving data shortages in AI adoption by leveraging generative AI and foundation models and simplifying complex implementation through zero-code. Its offerings aim to improve labor productivity by enabling rapid AI deployment in business workflows. The company plans to invest in new businesses, accelerate product R&D, construct recurring-revenue models, and expand sales and engineering hires. As of October 31, 2023, its stated capital (including capital reserve) was ¥946 million, and cumulative funding after the latest round is about ¥1.2 billion. RUTILEA is headquartered in Kyoto and led by CEO Takafumi Yano. RUTILEA offers zero-code AI products designed to simplify AI adoption and automate business processes to improve labor productivity. The company uses generative AI and foundation models to address data shortages that commonly hinder AI implementation and delivers solutions in a ready-to-use form. Since its founding in August 2018, RUTILEA has focused on making the AI introduction process simple through zero-code interfaces. The company plans to invest in new business initiatives, continue product R&D, build recurring-revenue models, and expand sales and engineering headcount. Financially, after a Series C1 in August 2023 the company reports cumulative funding of about ¥900M and capital (including reserves) of ¥675M as of 2023-09-01. RUTILEA is headquartered in Kyoto.

Led · Series B · Apr 2022

RVAC Medicines is an mRNA platform company incubated by CBC and headquartered in Singapore, building a pipeline of novel mRNA vaccines and therapeutics targeting infectious diseases, autoimmune diseases, and cancers. The company aims to develop a multivalent COVID vaccine and other mRNA innovations, with COVID candidates shown safe and efficacious in preclinical studies and planned to enter clinical studies in Q3 2022. RVAC leverages a strategic partnership with Acuitas Therapeutics for lipid nanoparticle delivery and is supported by a world-class scientific advisory board. Proceeds from its recent financing will fund preclinical and clinical development and the buildout of R&D and manufacturing capabilities. RVAC currently maintains R&D centers in Boston and Shanghai and plans new R&D and manufacturing facilities in Singapore and China, with initiatives expected to create over 100 jobs in Singapore. Since its inception in June 2021, the company has raised a total of US$140 million.

Participated · Equity · Aug 2019

Inflight VR develops a fully immersive VR entertainment solution tailored for transportation companies, delivered via individual stand-alone headsets. The company’s multinational team has deployed the product on buses, airlines and lounges across Asia, Europe, the Middle East and North America. Founded in 2014 and based in Munich and Barcelona, Inflight VR emphasizes seamless technical, commercial, logistic, usability and rights-management integration for customers. In its first year of operations the company secured eight customers and recorded over 95% positive passenger sentiment. The product supports ancillary revenue opportunities and the company plans to use fresh capital to expand rollouts across multiple travel industries and use cases. Management also intends to generate data on content performance, user behavior and business models to inform future deployments and monetization.

Participated · Series C · Jun 2018

I-Mab Biopharma is a Shanghai, China-based company focused on developing innovative biologics in immuno-oncology and immuno-inflammation. Led by founder and CEO Dr. Jingwu Zang, the company emphasizes target biology, antibody engineering, and pre-clinical and clinical development. It has rapidly built a globally competitive pipeline and currently has more than ten investigational drugs under development. I-Mab maintains partnerships with biotech and pharma firms such as Genexine, Ferring Pharmaceuticals and MorphoSys AG, and works with CROs including WuXi Biologics and TigerMed. The company completed a $220M Series C financing and intends to use the proceeds to advance the pre-clinical and clinical development of multiple Best-in-Class and First-in-Class assets.